Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH, somatoliberin). The molecule is a stabilized form of human GHRH(1-44): a trans-3-hexenoyl group is attached to the N-terminus, which slows enzymatic degradation of the peptide and prolongs its action compared with native GHRH. It matters to separate the classes at once: tesamorelin is specifically a GHRH analog, not a ghrelin mimetic (a growth-hormone secretagogue such as ipamorelin or a GHRP), so both its mechanism and its evidence base are its own.

Mechanism of action

Native GHRH is produced by the hypothalamus and stimulates the somatotrophs of the anterior pituitary to synthesize and secrete growth hormone (GH). Tesamorelin acts on the same GHRH receptors, enhancing the endogenous, pulsatile release of the body's own growth hormone rather than introducing exogenous GH. Indirectly this raises the level of insulin-like growth factor-1 (IGF-1), the main mediator of GH's systemic effects. Because the stimulus passes through the physiological hypothalamus-pituitary axis, negative feedback via somatostatin and IGF-1 is preserved. This makes the mechanism fundamentally different from direct administration of recombinant GH, where such self-regulation is bypassed.

What was studied

The best-documented use of tesamorelin is HIV-associated lipodystrophy with excess accumulation of visceral (intra-abdominal) fat. It is for this indication that the brand Egrifta received FDA (US Food and Drug Administration) approval in 2010, and it is here that the bulk of quality data is concentrated.

The evidence base rests on real randomized placebo-controlled trials (RCTs):

  • In a phase-3 study (Falutz et al., NEJM, 2007) daily subcutaneous injections of tesamorelin over 26 weeks significantly reduced the volume of visceral adipose tissue (measured by CT) versus placebo, while raising IGF-1. [1]
  • A pooled analysis of two phase-3 RCTs (Falutz et al., JCEM, 2010) confirmed the reduction in visceral fat and the effect on the lipid profile; importantly, the effect largely disappeared after discontinuation of the drug. [2]
  • Long-term data with a safety extension (Falutz et al., AIDS, 2008) assessed tolerability with prolonged use. [4]
  • Later work (Stanley et al., JAMA, 2014; Lancet HIV, 2019) studied the effect on liver fat and non-alcoholic fatty liver disease in patients with HIV. [3][5]

A key detail: virtually all quality data were obtained in a single population (people with HIV and abdominal obesity). This directly determines how correct it is to extrapolate the results to other groups.

Safety and limitations

Clinical trials recorded injection-site reactions, arthralgia, edema, as well as raised IGF-1 and changes in glucose-metabolism markers. Because the drug enhances GH/IGF-1 signaling, particular attention was paid to risks tied to fluid retention, insulin sensitivity and a theoretical oncological risk; tesamorelin is contraindicated in active malignancies and during pregnancy. The effect on visceral fat is reversible: after therapy stops the fat usually returns, so this is not a "one-time" solution.

Level of evidence: honestly

For the "HIV-associated lipodystrophy" indication the level of evidence is high: there are reproducible phase-3 RCTs and regulatory approval. Outside this indication, however (for "rejuvenation", muscle building, fat burning in healthy people or athletic goals), quality controlled studies are lacking. Such uses remain off-label and experimental, and most existing claims rest on extrapolation of the mechanism rather than on direct clinical data in the relevant populations. The honest wording here is "insufficient evidence", not "proven".

This material is strictly for research purposes (research-use-only). It is not medical advice, not an instruction for use and not a call to take it. Tesamorelin is not registered in Ukraine as a medicine for general use; any use is possible only within licensed laboratory research.